Oncopeptides Rescinds Pepaxto Voluntary Withdrawal, Which Could Set Up Battle With US FDA

 
• By Derrick Gingery
U-turn sign
An Oncopeptides executive said more information on the decision to rescind the withdrawal is expected in the coming months. • Source: Alamy

More from Clinical Trials

More from R&D